Open Payments

Newyork-Presbyterian/Queens

Type
Teaching hospital
Where
FLUSHING, NY
Medicare CCN
330055
Received
$408,652 in 41 records, 2022 ($167,161 general, $241,491 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment7$167,161
2022Research payment34$241,491

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.8$196,3832022
Novartis Pharmaceuticals Corporation4$120,4342022
Boston Scientific Corporation12$26,1792022
Volta Medical Inc6$23,1802022
SANOFI US SERVICES INC.4$20,5002022
Novocure Inc.1$13,8552022
BIOTRONIK INC.3$4,2242022
Aesculap, Inc.1$2,4972022
Abbott Laboratories1$9502022
Stryker Corporation1$4492022

By nature of payment

NatureRecordsAmount
Research payment34$241,491
Grant1$159,041
Debt forgiveness3$5,570
Consulting Fee3$2,550

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Gilead Sciences, Inc.$159,041GrantCash or cash equivalent2022
2022-12-31Stryker Corporation$449Debt forgivenessCash or cash equivalent2022
2022-12-22Abbott Laboratories$950Consulting FeeCash or cash equivalentALLURE Device, Cardiac Rhythm Management2022
2022-12-21Gilead Sciences, Inc.$1,404Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-12-12SANOFI US SERVICES INC.$1,500Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2022
2022-12-05SANOFI US SERVICES INC.$1,500Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2022
2022-12-01Volta Medical Inc$3,457Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-11-14SANOFI US SERVICES INC.$2,500Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2022
2022-10-31Aesculap, Inc.$2,497Debt forgivenessCash or cash equivalent2022
2022-10-18Volta Medical Inc$7,391Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-09-21Gilead Sciences, Inc.$1,202Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-09-06SANOFI US SERVICES INC.$15,000Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2022
2022-08-09Boston Scientific Corporation$10,000Research paymentCash or cash equivalentGENERAL - THERAPIES Device, THERAPIESCardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID19 Infection and to Predict Patte2022
2022-08-03Gilead Sciences, Inc.$13,180Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-08-01Gilead Sciences, Inc.$11,375Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-07-20Gilead Sciences, Inc.$7,575Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-07-20Gilead Sciences, Inc.$1,404Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-07-07Novartis Pharmaceuticals Corporation$60,027Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF)2022
2022-06-22Volta Medical Inc$4,400Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-06-21Volta Medical Inc$4,185Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-05-02Boston Scientific Corporation$164Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-04-18Novocure Inc.$13,855Research paymentCash or cash equivalentEF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi2022
2022-04-12BIOTRONIK INC.$400Consulting FeeCash or cash equivalentEdora 8 DR-T Device, Cardiology/Vascular Diseases2022
2022-04-06Boston Scientific Corporation$1,840Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-04-06Boston Scientific Corporation$517Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-04-06Boston Scientific Corporation$407Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-04-06Boston Scientific Corporation$245Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-04-06Boston Scientific Corporation$62Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-03-31BIOTRONIK INC.$2,624Debt forgivenessCash or cash equivalent2022
2022-03-21Boston Scientific Corporation$10,250Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTLUX TRENDS2022
2022-03-21Boston Scientific Corporation$1,500Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTLUX TRENDS2022
2022-03-18Volta Medical Inc$1,215Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-03-02Novartis Pharmaceuticals Corporation$59,681Research paymentCash or cash equivalentLEQVIO Drug, CARDIOVASCULARA RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING THE EFFECTIVENESS OF AN INCLISIRAN FIRST IMPLEMENTATION STRATEGY T2022
2022-02-23Gilead Sciences, Inc.$1,202Research paymentCash or cash equivalentA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2022
2022-02-22Volta Medical Inc$2,531Research paymentCash or cash equivalentVX1 Device, CARDIOVASCULARTailored AF2022
2022-02-10Novartis Pharmaceuticals Corporation$266Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARA MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ62022
2022-01-14Novartis Pharmaceuticals Corporation$459Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT 2022
2022-01-13Boston Scientific Corporation$110Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLONGEVITY STUDY2022
2022-01-11BIOTRONIK INC.$1,200Consulting FeeCash or cash equivalentEdora 8 DR-T Device, Cardiology/Vascular Diseases2022
2022-01-04Boston Scientific Corporation$818Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022
2022-01-04Boston Scientific Corporation$264Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CRMLUX TRENDS2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New York; placed by its state only.

MeasureState
New York
Population B0100319,852,366
Population, 2020 census P120,201,249
Median age B0100239.8
Under 18 B0100120.5%
65 and over B0100117.9%
Households B110017,722,646
Foreign born B0500222.8%
Median household income B19013$85,974
Median family income B19113$106,873
Per capita income B19301$50,712
Poverty rate B1700114.0%
Unemployment rate B230256.4%
Civilian labor force B2302510,171,766
Mean commute (minutes) B0801332.6
Bachelor's degree or higher B1500340.2%
Housing units B250018,585,241
Owner-occupied B2500354.3%
Renters B2500345.7%
Median home value B25077$423,800
Median gross rent B25064$1,621
White, not Hispanic B0300252.8%
Black B0300213.4%
Hispanic or Latino B0300219.8%
Asian B030029.0%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.